Balaxi Pharma Opens One-Year Window to Dematerialise Legacy Physical Shares

Balaxi Pharmaceuticals Limited ( (IN:BALAXI) ) has shared an update.

Balaxi Pharmaceuticals Limited has notified the stock exchange that it has published newspaper advertisements announcing a special one-year window for the transfer and dematerialisation of physical shares. The window, effective from 5 February 2026 to 4 February 2027, applies to physical share certificates relating to transactions executed before 1 April 2019 and allows shareholders to lodge or re-lodge pending or earlier transfer and demat requests.

The initiative, undertaken in line with a recent SEBI circular, is aimed at helping investors regularise older physical shareholdings and migrate them into electronic form. By facilitating compliance with updated market regulations and improving share transfer efficiency, the move is expected to enhance transparency in the company’s shareholding structure and reduce operational frictions for legacy investors.

More about Balaxi Pharmaceuticals Limited

Balaxi Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the manufacture and distribution of pharmaceutical products. The company is listed on the National Stock Exchange of India and serves a broad base of shareholders, including investors holding both dematerialised and legacy physical share certificates.

Average Trading Volume: 170,573

Technical Sentiment Signal: Sell

Current Market Cap: 1.11B INR

See more data about BALAXI stock on TipRanks’ Stock Analysis page.